XBiotech announces positive final efficacy results from Phase II TASKIN trial
XBIT•XBiotech said 49 of 80 patients (61.3%) in the vilamakitug arm were alive at 12 months, surpassing the efficacy threshold, compared with 44 of 79 patients (55.7%) in the control arm.
1. Trial results
XBiotech reported that 49 of 80 patients (61.3%) in the vilamakitug arm of its Phase II TASKIN trial were alive at 12 months, surpassing the efficacy threshold. In the control arm, 44 of 79 patients (55.7%) were alive at 12 months.
